For more information about products within the Pathway Portfolio, please click here for prescribing information
Cardiology
The Pathway Portfolio is Aspire Pharma’s branded generic portfolio with products covering a wide range of therapy areas, including: CNS, Respiratory, Cardiovascular, Pain and Urology.
Each product in the portfolio has its own key offerings, ranging from:
- A full range of strengths available1
- A first strength to market1
- Simpler dosing which may help some patients with concordance and compliance1-2
- The first brand to market1
All of which create a wider offering to patients.
Pathway to Partnership:
Trusted Brands:
- Bioequivalent to brand originators3
- Available from mainline wholesalers
Bespoke Support:
- Price guarantee
- Individualised rebates on request
Delofine® XL (felodipine) prolonged-release tablets
Indicated for the treatment of hypertension and stable angina pectoris4.
The most cost-effective, full range of felodipine prolonged-release tablets, saving up to 59% across all strengths on the UK Drug Tariffs1.
Delofine® XL could reduce the average ICS/ICB prescribing costs of felodipine prolonged release tablets by an average of £254,937 per annum, saving up to £10.7 million annually across the NHS5*.
References:
*Average ICS is based on 4 x Moving Quarterly Turnover (MQT) divided by 42 ICS/ICB’s
- UK Drug Tariff (accessed October 2024)
- Kyoko Higashiet al. Dosing frequency and adherence in chronic psychiatric disease: systematic review and meta-analysis. Neuropsychiatric Disease and Treatment, 2013; 9: 119–131 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3552550/
- Data on file, 10103111700 v 2.0 October 2024 Bioequivalence data
- Delofine® XL SmPC (accessed October 2024)
- Insypher 10100831045 v 21.0 August 2024, GPPLPD Date Range: May-24 – Jul-24
XLW1010311F2_OCT2024
